Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases

Clicks: 413
ID: 113248
1996
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #40 of 581 articles by views in pediatrics

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 581 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The purpose of this statement is to inform practitioners about new information concerning lack of demonstrated clinical effectiveness of ribavirin in the treatment of infants with respiratory syncytial virus (RSV) disease. The intent of the new recommendation is to allow practitioners to decide whet …
Reference Key
1996pediatricsreassessment Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;
Journal pediatrics
Year 1996
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8545210
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review clinical trials as topic humans pubmed abstract nih national institutes of health national library of medicine treatment outcome practice guideline guideline antiviral agents / therapeutic use* ribavirin / therapeutic use* respiratory syncytial virus infections / drug therapy* research design pmid:8545210 bias

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.